Top US exchange executives call for clearer rules as prediction markets grow

Executives from major U.S. exchanges urged consistent regulation of prediction markets to protect investors and prevent manipulation, with Nasdaq engaging the SEC to fit prediction products within existing options rule frameworks. The sector has surged since the 2024 U.S. presidential race and drawn billions in funding—ICE committed up to $2.0 billion to Polymarket—and CME launched a prediction platform in five U.S. states with FanDuel. Exchanges view prediction markets as a new derivatives frontier to diversify revenue, but regulatory clarity and anti-manipulation safeguards will determine adoption and scale.

Analysis

Regulatory standardization of prediction markets is a structural win for well-capitalized, regulated exchanges because it converts a nascent, low-fee retail activity into an addressable, high-frequency derivatives product that sits squarely inside their existing clearing, surveillance and market-data franchises. If even 1–3% of retail/crypto-native flow migrates onto regulated venues over 12–24 months, conservatively this could translate into incremental annual fee pools in the tens-to-low-hundreds of millions for an exchange with global reach, while also creating sticky data/IP streams that command premium distribution fees.

The primary near-term cost is compliance build-out: expect months-to-year engineering and legal efforts and upfront spending in the low tens of millions per firm, with tail litigation risk if manipulation incidents occur. A bifurcated regulatory landscape (state approvals vs federal rulemaking) is the main execution risk — a messy, multi-jurisdiction rollout could compress early revenue and amplify go-to-market costs, delaying payback to 12–36 months.

Second-order dynamics favor firms that control clearing and custody because customer protection rules will push counterparties to regulated CCPs and insured custody solutions. That raises the value of exchange-owned clearinghouses and custody rails, and creates cross-sell optionality (clearing fees, margin financing, data licenses). The market is underestimating how quickly regulation could erect barriers to entry: incumbents will be able to monetize aggregated probability data and surveillance tooling, making this less a consumer product and more a regulated B2B data/clearing play over the next 2–4 years.

Key Decisions for Investors

• Long ICE (12–18 months): Buy ICE stock sized 1.5% of book. Thesis: superior clearing/custody cross-sell and existing data distribution will capture most initial regulated prediction-market flow. Target +25% if federal rulemaking affirms incumbents within 12 months; stop -10% on regulatory delays or adverse rulings.
• Pair trade — Long CME / Short NDAQ (6–12 months): Size 1% long CME, 1% short NDAQ. Rationale: CME’s operational fit for novel derivatives vs Nasdaq’s smaller derivatives footprint. Target 10–15% relative outperformance; unwind if both names rally >20% on broad market impulse.
• Options play on CME (9 months): Buy a 1.5x notional call spread (buy calls, sell higher strike calls) to cap premium. Allocate 0.5% notional. Reward: asymmetric upside to capture re-rating if product launches succeed; risk: premium loss if rollout stalls.
• Event hedge: Buy short-dated puts on all three (staggered expiries 3–9 months) totaling 0.5–1% notional to protect against a regulatory shock or a high-profile manipulation incident that could trigger fines or shelf-freezes.